Supersaturated Oxygen Therapy Study to Assess Utility, Cost-effectiveness
The first patient has enrolled in a study to assess the clinical utility and cost-effectiveness of Zoll TherOx SuperSaturated Oxygen (SSO2) Therapy.
The first patient has enrolled in a study to assess the clinical utility and cost-effectiveness of Zoll TherOx SuperSaturated Oxygen (SSO2) Therapy.
The first patient has enrolled in a study to assess the clinical utility and cost-effectiveness of Zoll TherOx SuperSaturated Oxygen (SSO2) Therapy.
Read MoreZoll Medical Corp’s TherOx SuperSaturated Oxygen (SSO2) Therapy has been awarded a group purchasing agreement for Diagnostic and Interventional Cardiology Catheters (DIC) with Premier Inc, effective as of July 1, 2022.
Read MoreZoll will exhibit its TherOx SuperSaturated Oxygen (SSO2) Therapy at the Vizient Innovative Technology Exchange on October 17.
Read MoreThe Centers for Medicare & Medicaid Services issued a new ICD-10-PCS code for TherOx SuperSaturated Oxygen (SSO2) Therapy, according to Zoll Medical Corp.
Read MoreThe US FDA approved an investigational device exemption (IDE) for a study evaluating the use of TherOx SuperSaturated Oxygen (SSO2) Therapy in patients presenting with STEMI and cardiogenic shock.
Read More